Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends

Impact · against what's priced in

The article provides no new catalyst for AbbVie, as its dividend history and the success of Skyrizi and Rinvoq are already core assumptions of the current stock price. Pfizer remains under pressure due to the well-known evaporation of COVID-19 vaccine revenue and upcoming patent cliffs.

ABBV+0.00: Already priced in
The price assumes: SKYRIZI and RINVOQ replacing HUMIRA's lost revenue
The article highlights the growth of Skyrizi and Rinvoq and the successful offset of Humira's exclusivity loss, but these are already fully reflected in the price.
What ABBV's price assumes · Sep 4

Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends

valuation
healthcare
pharmaceuticals
ABBV
PFE
dividend investing
dividend kings
income stocks
patent cliff

Search tags

Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends

What matters in this story

Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady

Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends

What matters in this story

Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady

How each ticker is affected

Connected tickers

Track these names every morning.

Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher

Why is Moderna down 10% on Friday?

Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?

Defiance CEO on Motivation Behind First Autism ETF

Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends

What matters in this story

Next reads from the same story arc

Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady

Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends

What matters in this story

Next reads from the same story arc

Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady

How each ticker is affected

Connected tickers

Track these names every morning.

Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher

Why is Moderna down 10% on Friday?

Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?

Defiance CEO on Motivation Behind First Autism ETF